Pharsight

Drugs that contain Secnidazole

1. Solosec patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324721 LUPIN Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(11 years from now)

US11602522 LUPIN Secnidazole for use in the treatment of sexually transmitted infection
Sep, 2035

(11 years from now)

US10849884 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US10857133 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US10682338 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11000508 LUPIN Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(11 years from now)

US11000507 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11020377 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US10335390 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11684607 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2022
New Indication(I-866) Jun 30, 2024
New Patient Population(NPP) Jan 26, 2025
Generating Antibiotic Incentives Now(GAIN) Sep 15, 2027

NCE-1 date: 15 September, 2026

Market Authorisation Date: 15 September, 2017

Treatment: Treatment of trichomoniasis in patients 12 years of age and older; Treatment of bacterial vaginosis in adult women; Treatment of bacterial vaginosis in female patients 12 years of age and older

Dosage: GRANULE;ORAL

More Information on Dosage

SOLOSEC family patents

Family Patents